Kura Oncology (KURA) investor relations material

Executive summary

• KOMZIFTI (ziftomenib) achieved majority share of new patient starts in relapsed/refractory NPM1-mutated AML menin inhibitor market in its second full commercial quarter, generating $9.1 million in net product revenue in Q2 2026, up 57% from Q1, with 115 new patient starts and over 250 total prescriptions.

• Physician adoption is expanding, with 40% of new patient starts involving combination therapy, and coverage now exceeds 95% of insured lives, including 16 million with preferred status.

• Darlifarnib demonstrated strong response rates in renal cell carcinoma and KRAS-mutated solid tumors, with up to 67% ORR in pancreatic cancer, 50% in NSCLC, and up to 50% in cabozantinib-naïve ccRCC.

• The company maintains a strong financial position with $519 million in cash, equivalents, and short-term investments as of June 30, 2026, and $180 million in anticipated collaboration payments.

• Strategic collaborations, including with Kyowa Kirin, support broad development and commercialization of ziftomenib, with Kura retaining key U.S. rights.

Financial highlights

• Net product revenue from KOMZIFTI sales was $9.1 million in Q2 2026, up 57% over Q1, and $14.9 million for the six months ended June 30, 2026.

• Collaboration revenue from Kyowa Kirin was $11.8 million in Q2 2026 and $24.3 million for the first half of 2026.

• Research and development expenses were $61.9 million in Q2 2026 and $127.2 million for the first half of 2026.

• Selling, general, and administrative expenses increased to $31.8 million in Q2 2026 and $63.3 million for the first half of 2026.

• Net loss was $68.3 million in Q2 2026 and $141.7 million for the first half of 2026.

Outlook and guidance

• Cash and anticipated collaboration payments are expected to fund the ziftomenib AML program through topline Phase 3 results in 2028.

• Multiple clinical updates and data readouts for ziftomenib and darlifarnib are expected in the second half of 2026 and 2027.

• Enrollment for the pivotal KOMET-017 trial is progressing, with topline results expected in 2028.